Videos

The key opinion leaders explore strategies for integrating newly available diagnostic tests into the existing treatment paradigm and patient journey.

The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.

"I think it's going to help younger or less experienced urologists get more proficient at this procedure faster. That's where the AI is going to come into play," says Lewis S. Kriteman, MD, FACS.

A medical expert discusses how emerging copper-based developments in PSMA imaging, particularly the 64Cu-SAR-bisPSMA agent, offer advancements in tumor detection and imaging logistics compared to traditional agents.

A medical expert discusses how advancements in PSMA PET imaging, including the development of agents like 64Cu-SAR-bisPSMA, address current challenges in sensitivity and logistical issues, potentially enhancing tumor detection and patient outcomes.

“In the period where a patient receives a diagnosis of favorable intermediate-risk cancer or higher and doesn't know what to do, there is a big unmet need/gap that we aim to serve with Unfold AI,” says Shyam Natarajan, PhD.

“I think that there will probably be much more accessible tools within the next 5 years, and almost certainly within the next 10 years,” says Yair Lotan, MD.

"It's really upon us, as the medical community, to be better about not just antibiotic stewardship, but also diagnostic stewardship," says A. Lenore Ackerman, MD, PhD.

"That's probably the biggest thing that I would say to somebody who's interested in urology is, do you think you can get on another patient's level?" says Emily Sopko, CNP.

"What we demonstrated was that at 30-day and 90-day interval outcomes, the patients actually had equivalent safety profiles compared to traditional ureteroscopy with basketing," says Thomas Chi, MD, MBA.

Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.

Dean Elterman, MD, discusses how a comprehensive approach to diagnosing and managing benign prostatic hyperplasia (BPH) involves a combination of symptom assessment, lifestyle modifications, pharmacotherapy, and regular follow-up to optimize patient outcomes.

"We see use of AI-generated cancer maps in the decision-making process of understanding who is the right patient for what therapy, as well as planning out the specific therapy," says Shyam Natarajan, PhD.

"I like working alongside the residents, because they've taught me pretty much everything that I know about urology," says Emily Sopko, CNP.

“So, I think we have to be conscious that when we're developing these tools that we're inclusive,” says Yair Lotan, MD.

"We found that the performance of Unfold AI was actually an AUC of .89," says Shyam Natarajan, PhD.

“The technology is there, the experience is there now, and it's bringing it all together to lead to better outcomes [and a] shorter hospital stay,” says Kevin C. Zorn, MD, FRCSC, FACS.

"Often, we can do flexible cystoscopies for difficult Foley placements, or if we need to remove an indwelling stent at the bedside, I can assist with those things," says Emily Sopko, CNP.

The panel explores the role of biomarkers in monitoring disease progression for prostate cancer patients on active surveillance, discussing how these tests aid in detecting changes that may warrant intervention.

The panel examines the challenges associated with effectively interpreting and applying biomarker test results in prostate cancer management and treatment decision-making.

“It's still relatively early, but this study in close to 1000 patients validated this algorithm, and it's now being studied prospectively as well,” says Yair Lotan, MD.

"From the perspective of lifestyle medicine, what is most important is what the patient is most motivated to work on in the here and now," says Stacy Loeb, MD, MSc, PhD (Hon).

Panelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.

Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.

“You're going to be able to use these catheters over time, for long periods," says Ana Lidia Flores-Mireles, PhD.

“Even if they're postmenopausal, we remove the ovaries, which puts them at a higher risk for other complications such as osteopenia,” says Laura Bukavina, MD, MPH, MSc.

"I'm able to really dedicate a lot of my time to patients and families for education," says Emily Sopko, CNP.

“There's definitely a lot of hype around the concept of artificial intelligence, and I think we're in the early phases of trying to figure out where it makes sense to adopt the technology and how to incorporate into clinical care,” says Yair Lotan, MD.

Dean Elterman, MD, discusses real-world outcomes of minimally invasive surgical therapies for benign prostate dysplasia, including improvements in quality of life, symptom relief, comparisons with clinical study results, and general patient feedback, while also sharing tips for building rapport and educating patients on their treatment options.

Dean Elterman, MD, compares minimally invasive surgical therapy (MIST) options for prostate treatment, discussing factors influencing choice, patient experience differences, and clinical and nonclinical factors such as prostate size, symptom severity, and patient preferences.